anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a rapid autism screening system which comprises an eye movement tracking device and a screening server. The eye tracking device comprises a fixation target unit, a target stimulation unit and an eye movement information acquisition unit. The gaze target unit is for presenting a target for gaze on a screen. The target stimulation unit is used for providing stimulation to the watching target unit so as to enable the watching target unit to appear, disappear or move. The eye movement information acquisition unit is used for acquiring eye position changes when the eyes appear, disappear or move along with the gazing target unit. The screening server comprises an eye movement track calculation unit and a determination unit, the eye movement track calculation unit calculates the fixation time percentage based on the eye position change fed back by the eye movement information acquisition unit, and the determination unit obtains the screening result based on the fixation time percentage. The eye movement tracking device is used for the rapid screening of the autism, accords with the cognitive development characteristics of the infants, and is good in reliability, simple to operate and easy to implement.
Patients with CRC with a HER2 activating mutation will receive poziotinib 8 mg, orally, BID starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
Alopecia areata (AA) is a complex autoimmune disorder with an estimated lifetime risk of 1.7% where both genetic pre-disposition and environmental factors contribute. It typically presents with sharply demarcated round patches of non-scarring hair loss that may present at any age. Current medical therapies (topical or systemic) for AA are not reliably effective, particularly for severe disease and there is no robust evidence from high-quality randomized controlled trials. Patients with AA experience significant mental health and health related quality of life (HRQoL) impairment. Furthermore, at the country level, skin conditions such as AA ranged from 2nd to 11th leading cause of years lived with disability. It was shown that AA appears to affect all countries across the world similarly, and the health burden has remained stable despite substantial advances in healthcare and health-related resources. More recently, Mesinkovska et al demonstrated that the impact of AA extends beyond cosmetic concerns and carries a considerable psychosocial burden.

Many patients with AA are dissatisfied with current medical treatments and use alternative therapies and cosmetics. Cosmetics and not reimbursed treatments can weigh heavily on patients spending.This study will generate new data on the current situation of psychosocial and financial burden of AA. It will help to identify unmet needs and to understand the disease issues. It will also be the basis for the planification of future supporting measures.
Weekly phone calls by lay trained personnel to deliver problem solving therapy. Combined with a one-time cash transfer of Rs.1000.
FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
The invention discloses herpes zoster mRNA and application thereof, and belongs to the technical field of biomedicine. The herpes zoster mRNA of the invention comprises the following structure: A1-A2-A3-poly (A); a1 is a 5' -UTR sequence; a2 is the optimized coding sequence of the glycoprotein gE of the herpes zoster virus; a3 is the 3' -UTR sequence; poly (a) is polyadenylation; the nucleotide sequences of 5'-UTR, 3' -UTR and herpes zoster virus glycoprotein gE are respectively shown as SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO. 1. The invention discloses application of the mRNA in preparing a medicament for preventing and/or treating herpes zoster. The vaccine disclosed by the invention comprises the mRNA and a vector. The invention analyzes the immunological characteristics of the VZV coding antigen protein in detail, and designs an mRNA vaccine aiming at glycoprotein E by utilizing the characteristics of the antigen protein coding gene. The vaccine has better immunogenicity, can generate higher neutralizing antibodies compared with protein vaccine, and can induce specific CD  4   +  T cells of the VZV virus; the dependence on adjuvants is reduced.
This is a 12-week, prospective, randomized clinical trial of the moderating effect of rs2832407 on the efficacy of topiramate in reducing HD in 200 individuals of European descent with DSM-5 AUD. The investigators will stratify the randomization on genotype and oversample rs2832407\*C homozygotes, the most topiramate-responsive genotype, to ensure comparable numbers of subjects in the four medication x genotype groups. The investigators will compare the efficacy of topiramate to placebo in reducing the frequency of HDDs in subjects with AUD using a two-arm, parallel-groups design. Subjects will either have a goal of reducing their drinking to safe levels or abstinence.

The investigators will use daily data collection to examine changes in relevant process variables and their interaction with genotype and medication group as predictors of HD. At each visit, all subjects will receive Medication Management (Pettinati, Weiss et al. 2004), which was developed for the COMBINE Trial and which the investigators modified to be relevant for both reducing heavy drinking and promoting abstinence. Random assignment to treatment group and double-blind conditions will be maintained throughout the study. Raters will be trained in the reliable use of all assessments. The investigators will use serum GGTP and percent disialotransferrin (%dCDT), an improved assay for carbohydrate deficient transferrin, to validate subject reports. Following a one-week pre-treatment assessment period, subjects will receive 12 weeks of treatment, after which there will be a 6-day taper period, during which subjects will reduce their dosage of topiramate gradually and then discontinue it completely. Daily reports during the treatment period will be obtained using interactive voice response (IVR) to identify subjective correlates of medication effects and to monitor medication use. Following the 12-week treatment period, subjects will be asked to return to the clinic for 3-month and 6-month post-treatment follow-up visits to evaluate the durability of treatment effects.

Two hundred men and women of European descent will be randomized to study medication. Subjects will be recruited using referrals from treatment programs throughout Philadelphia; IRB-approved advertisements on mass transit, on local radio and television stations and in newspapers, social media, and broadcast email messages at institutions that offer such a service and by posting/distributing recruitment materials in community and college settings. Respondents will initially be evaluated by telephone prior to an in-person visit to the Treatment Research Center of the University of Pennsylvania Perelman School of Medicine. The investigators will select subjects based on their genotype to ensure comparable numbers of individuals who are rs2832407\*C-allele homozygotes and A-allele carriers. The investigators will block randomize subjects to balance the groups on treatment goal (i.e., reduced drinking or abstinence).
A bed (home care apparatus)(1) where individual drive sections for a head section (12), a leg section (13), a height adjustment section (14) are operated by motors (15a-15c) and actuators (16a-16c) based on switch operation. Operating conditions of the drive sections are detected by sensors (17a-17c). A means (21) for operating and controlling the individual sections grasps operating conditions of a drive section based on a detection signal and stores, as operation history information, an operation history of the drive section in an operation history storage section (22). Operation history information in the operation history storage section (22) is transmitted to a host computer (4) by a communication unit (7). The host computer (4) processes the received operation history information into data that can be displayed in the form of animation, graphs, and accumulated time and send the data to a computer (5) etc. connected by the Internet.
PURPOSE OF THE REVIEW: Osteosarcopenia is a geriatric syndrome associated with disability and mortality. This review summarizes the key microRNAs that regulate the hallmarks of sarcopenia and osteoporosis. Our objective was to identify components similarly regulated in the pathology and have therapeutic potential by influencing crucial cellular processes in both bone and skeletal muscle.
RECENT FINDINGS: The simultaneous decline in bone and muscle in osteosarcopenia involves a complex crosstalk between these tissues. Recent studies have uncovered several key mechanisms underlying this condition, including the disruption of cellular signaling pathways that regulate bone remodeling and muscle function and regeneration. Accordingly, emerging evidence reveals that dysregulation of microRNAs plays a significant role in the development of each of these hallmarks of osteosarcopenia. Although the recent recognition of osteosarcopenia as a single diagnosis of bone and muscle deterioration has provided new insights into the mechanisms of these underlying age-related diseases, several knowledge gaps have emerged, and a deeper understanding of the role of common microRNAs is still required. In this study, we summarize current evidence on the roles of microRNAs in the pathogenesis of osteosarcopenia and identify potential microRNA targets for treating this condition. Among these, microRNAs-29b and -128 are upregulated in the disease and exert adverse effects by inhibiting IGF-1 and SIRT1, making them potential targets for developing inhibitors of their activity. MicroRNA-21 is closely associated with the occurrence of muscle and bone loss. Conversely, microRNA-199b is downregulated in the disease, and its reduced activity may be related to increased myostatin and GSK3β activity, presenting it as a target for developing analogues that restore its function. Finally, microRNA-672 stands out for its ability to protect skeletal muscle and bone when expressed in the disease, highlighting its potential as a possible therapy for osteosarcopenia.
With the progress and development of medical technology, the mortality rate of critically ill children continues to decline. To improve the long-term prognosis of children has become a new goal of modern medicine. Sleep disorders in critically ill children are caused by disease factors, the complex environment of ICU, and various treatment factors, which have seriously affected the patient's rehabilitation and long-term quality of life. Attention should be paid to the sleep disorders in critically ill children. At present, the research on sleep disorders in critically ill patients in China is mostly focused on adults, and the critically ill children are rarely involved, and there is no research related to sleep disorders and recovery tracks of critically ill children. This prospective longitudinal mixed study aims to describe the change trajectory of sleep disorder and recovery in critically ill children and provide suggestions for subsequent clinical workers to formulate reasonable intervention measures.
PURPOSE:The titled drug capable of being directly inserted and applied to the affected part, obtained by pulverizing polyglycollic acid or a glycollic acid- lactic acid copolymer, deaerating and drying it under reduced pressure, blending it with a drug, preheating the blend, feeding it to a mold at constant temperature under pressure, molding it. CONSTITUTION:Polyglycollic acid or a glycollic acid-lactic acid copolymer having >=80wt% polyglycollic acid is pulverized, deaerate and dried at 100-200 deg.C under 5-10mm.Hg reduced pressure for 2-3hr, low-volatile components in the polymer are completely volatilized. 100pts.wt. above-mentioned polymer is mixed with 20-40pts.wt. drug (e.g., carcinostatic agent such as 5-fluorouracil, etc.), preheated, fed to a mold kept at 195-235 deg.C, and molded into a needle-like material having 1.5mm. diameter and about 3cm length. The strength of the molded drug is raised by the deaeration treatment, and low-boiling organic impurities and air will not get into the body.
In rats treated with cyclobenzaprine for up to 67 weeks at doses of approximately 5 to 40 times the maximum recommended human dose, pale, sometimes enlarged, livers were noted and there was a dose-related hepatocyte vacuolation with lipidosis. In the higher dose groups, this microscopic change was seen after 26 weeks and even earlier in rats that died prior to 26 weeks; at lower doses, the change was not seen until after 26 weeks. Cyclobenzaprine did not affect the onset, incidence, or distribution of neoplasia in an 81-week study in the mouse or in a 105-week study in the rat. At oral doses of up to 10 times the human dose, cyclobenzaprine did not adversely affect the reproductive performance or fertility of male or female rats. Cyclobenzaprine did not demonstrate mutagenic activity in the male mouse at dose levels of up to 20 times the human dose.

A battery of mutagenicity tests using bacterial and mammalian systems for point mutations and cytogenic effects have provided no evidence for a mutagenic potential for cyclobenzaprine. An in vivo mouse bone micronucleus assay, an assessment of chromosomal aberrations (Chinese hamster ovary), and a mammalian microsome reverse mutation assay were negative.
Participants will be enrolled postpartum within 6-12 weeks after delivery. Participants will receive a fixed-dose combination of FTC/TDF once daily under direct observation from Day 0 through Week 12.
Vascular depression is a condition that typically affects the elderly and is associated with small vascular lesions. It is more resistant to treatment and has a poorer outcome than nonvascular depression. By altering excitability in the cortical area of the brain, rTMS may be an effective treatment neuropsychiatric conditions, particularly depression.

Participants in this study will be randomly assigned to 15 treatments of either rTMS or sham rTMS for 3 weeks. Following treatment, participants will receive citalopram for 9 weeks. Response rates to treatment; relapse rates; the size, number, and location of the vascular lesions; and the amount of regional brain atrophy will be measured. Improvements in activities of daily living, quality of life, and cognitive function will also be also measured.
The plant cytoskeletal proteins play a key role that control cytoskeleton dynamics, contributing to crucial biological processes such as cell wall morphogenesis, stomatal conductance and abscisic acid accumulation in repercussion to water-deficit stress or dehydration. Yet, it is still completely unknown which specific biochemical processes and regulatory mechanisms the cytoskeleton uses to drive dehydration tolerance. To better understand the role of cytoskeleton, we developed the dehydration-responsive cytoskeletal proteome map of a resilient rice cultivar. Initially, four-week-old rice plants were exposed to progressive dehydration, and the magnitude of dehydration-induced compensatory physiological responses was monitored in terms of physicochemical indices. The organelle fractionation in conjunction with label-free quantitative proteome analysis led to the identification of 955 dehydration-responsive cytoskeletal proteins (DRCPs). To our knowledge, this is the first report of a stress-responsive plant cytoskeletal proteome, representing the largest inventory of cytoskeleton and cytoskeleton-associated proteins. The DRCPs were apparently involved in a wide array of intra-cellular molecules transportation, organelles positioning, cytoskeleton organization followed by different metabolic processes including amino acid metabolism. These findings presented open a unique view on global regulation of plant cytoskeletal proteome is intimately linked to cellular metabolic rewiring of adaptive responses, and potentially confer dehydration tolerance, especially in rice, and other crop species, in general.
Participants first received the Life Story Book Intervention once a week for 3 weeks. After a washout period of 1 week, they then received the Usual Care Intervention for 3 weeks. Posttests were then conducted for 1 week.
1282581 Condensed adamantane-pyrrolidines E R SQUIBB & SONS Inc 24 July 1969 [24 July 1968] 32940/69 Heading C2C Novel compounds I (including acid addition and quaternary ammonium salts thereof) wherein Y is C 3-10  cycloalkyl, allyl, R 0  and R are H, alkyl, alkoxy or phenyl, m is 0 or 1 to 4, n is 1 to 4, B signifies -NR 1 R 2  or 5-, 6- or 7-membered N-heterocyclic radical (may be substituted and has less than 12 atoms excluding H atoms) and R 1  and R 2  are H, alkyl or adamantyl, are obtained: (a) by ring closing compounds II (prepared, e.g. by reacting the corresponding secondary amine with N-chlorosuccinimide; R 3  is alkyl, e.g. ethyl) in the presence of 85% sulphuric acid or by utilizing photolysis to afford I in which Y is alkyl; dealkylation affords I in which Y is H; (b) by ring closing azides III (obtained by reacting the appropriate 1-adamantane-ethanol tosylate with sodium or potassium azide) to afford I in which Y is H; (c) by reducing a pyrrolidone IV with lithium aluminium hydride which pyrrolidone is itself obtained by irradiation of acid azide V (obtained from the corresponding acid chloride) with ultra-violet light or (d) by reacting I in which Y is H with halogen-Y (Y is not H). The foregoing secondary amine (the hydrochloride thereof is also described) is obtained by treating N - [2 - (1 - adamantane)ethyl] - acetamide (prepared via the following compounds: 1- adamantane-acetic acid, acid chloride thereof, 1- adamantane-acetamide and 1-adamantane-ethylamine; the latter, the hydrochloride of which is also described, is then treated with acetyl chloride) with lithium aluminium hydride. The foregoing tosylate is obtained by the interaction of p-toluenesulphonyl chloride and 1- adamantane-ethanol (prepared by interacting 1- adamantane-acetic acid and lithium aluminium hydride). Pharmaceutical preparations useful as antiviral agents contain as active ingredient compounds I; administration is, e.g. orally or parenterally or by vapour or spray through the mouth or nasal passages.
Background: The aim of this study was to determine the effect of PMR and nature sounds on nursing students' BPM skills, and anxiety levels and vital signs.

Methods: This was a randomized controlled experimental study conducted at the nursing department of the faculty of health sciences of a university. PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises. PMR+NS participants practiced PMR accompanied by nature sounds.
BACKGROUND: Vaginal rings formulated to deliver two drugs simultaneously have potential as user-controlled, long-acting methods for dual prevention of HIV and pregnancy.
METHODS: Two phase 1 randomized trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019) respectively enrolled 24 and 25 healthy, HIV-negative participants to evaluate safety, pharmacokinetics, and vaginal bleeding associated with use of a vaginal ring containing 200mg dapivirine (DPV) and 320mg levonorgestrel (LNG) designed for 90-day use. MTN-030/IPM 041 compared the DPV/LNG ring to a DPV-only ring (200mg) over 14 days of use. MTN-044/IPM 053/CCN019 compared continuous or cyclic use of the DPV/LNG ring over 90 days of use. Safety was assessed by recording adverse events (AEs). DPV and LNG concentrations were quantified in plasma, cervicovaginal fluid, and cervical tissue. Vaginal bleeding was self-reported.
RESULTS: There were no differences in the proportion of participants with grade ≥2 genitourinary AEs or grade ≥3 AEs with DPV/LNG ring vs. DPV ring use (p = .22), or with DPV/LNG ring continuous vs. cyclic use (p = .67). Higher plasma DPV concentrations were observed in users of DPV/LNG compared to DPV-only rings (Cmax p = 0.049; AUC p = 0.091). Plasma DPV and LNG concentrations were comparable with continuous and cyclic use (Cmax p = 0.74; AUC p = 0.25). With cyclic use, median nadir plasma DPV concentration was approximately 300 pg/mL two days after removal and median t1/2 for cervicovaginal fluid DPV concentration was 5.76 hours (n = 3). Overall bleeding experiences did not differ between continuous and cyclic users (p = 0.12).
CONCLUSIONS: The extended duration DPV/ LNG rings were well tolerated and the observed DPV concentrations in plasma and cervicovaginal fluid when used continuously exceeded concentrations observed in previous DPV ring efficacy studies. LNG concentrations in plasma were comparable with other efficacious LNG-based contraceptives. Genital DPV concentrations had a short half-life and were thus not well sustained following ring removal.
Sixty patients with Chronic Obstructive Pulmonary Disease (COPD) will be randomly assigned to the experimental (EX) group and the control group (CON). The participants' age will be 55 years and above with history of COPD. The Ex group will attend 4 sessions/week of Manual Diaphragm Release Technique Combined with Deep Breathing (10:15-min) for 8 weeks, the CON will attend 4 sessions/week of Deep Breathing (10:15-min) for 8 weeks. The stepping reaction time will be assessed by the choice stepping reaction time (CSRT). The Balance will be determined using a Time up and Go test (TUG) an d Berg balance scale (BBS). All the outcomes will be examined at baseline, and 8 weeks of the intervention.
According to TCM cakes provided by the invention, different single Chinese herbs and various traditional Chinese medicinal materials prescribed in a TCM set prescription of the National pharmacopoeia criterion are machined and crushed as bulk pharmaceutical chemicals specified in the national standard. TCM powders are compressed, molded and packaged into TCM cakes with folding lines thereon and in the shape of standardized geometry according to the grammages of dosages according to the different dosages of the common usage of the above single Chinese herbs and the TCM set prescription. The TCM cakes are sanitary, clean, standard in specification, accurate to meter, and convenient to carry about and store. TCM cake products can be informative, so that the quality management of products is facilitated. The modified usage of traditional TCM decoctions is reserved by the TCM cakes, so that the particularity of each patient or various diseases can be fully taken care of. Meanwhile, the advantages of traditional TCM decoctions are reserved, and the curative effect of the TCM is improved. The TCM cakes are good in promotion and application value. Through widely promoting and applying the TCM cakes, good economic and social benefits can be obtained.